We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Chicken Segment Drive Tyson Foods' (TSN) Q3 Earnings?
Read MoreHide Full Article
Tyson Foods, Inc. (TSN - Free Report) is scheduled to release third-quarter fiscal 2019 results on Aug 5. This renowned meat products company’s earnings have outpaced the Zacks Consensus Estimate, with average of 10.2% in the trailing four quarters.
Let’s see what’s in store for the company this time around.
McCormick & Company, Incorporated Price and EPS Surprise
The Zacks Consensus Estimate for earnings in the third quarter has remained unchanged in the past 30 days at $1.47, indicating a decline from $1.50 reported in the year-ago quarter. The consensus mark for revenues is $11,108 million, implying an increase of 10.5% from the year-ago quarter’s reported figure.
Factors Likely to Drive Tyson Foods
Tyson Foods is likely to gain from its Chicken and Beef segments, given the rising demand for protein. Notably, the company boasts a rich portfolio of protein-packed brands, the demand for which is growing rapidly across the globe. To this end, the company has also been undertaking acquisitions alongside offloading certain non-protein businesses. In particular, acquisitions are aiding growth in the Chicken segment and are likely to be a key driver in the quarter to be reported. Notably, the company acquired the Keystone Foods business in November 2018, which is expected to keep bolstering its Chicken and Other segments' performance.
Other notable acquisitions of Tyson Foods in the past include AdvancePierre and Original Philly Holdings. Also, the company has acquired poultry rendering and blending assets of AMPRO Products, Inc. and American Proteins, Inc. This has enabled Tyson Foods to bolster animal products recycling capabilities, which will aid in expanding the animal feed business. Apart from this, the company is likely to benefit from its focus on alternative sources for meat and protein products, evident from its investments in Beyond Meat and Memphis Meats.
Hurdles in the Path
Lower sales in the Pork and Prepared Foods categories have been weighing on the company’s top-line performance. While Pork segment sales were hurt by lower average sale price, the performance of the Prepared Foods category has been bearing the brunt of business divestitures. Also, input costs in the Prepared Foods category are expected to rise during the third and fourth quarters of fiscal 2019, owing to higher price of beef and pork stemming from the concerns regarding the outbreak of African swine fever in China. This poses a threat to the bottom line.
What the Zacks Model Unveils
Our proven model doesn’t conclusively predict a beat for Tyson Foods this earnings season. For this to happen, a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). You can uncover the best stocks to buy or sell before they’re reported with ourEarnings ESP Filter.
Though Tyson Foods carries a Zacks Rank #3, it has an Earnings ESP of 0.00%, which makes surprise prediction difficult.
General Mills (GIS - Free Report) presently has an Earnings ESP of +0.97% and a Zacks Rank #2.
Kraft Heinz (KHC - Free Report) currently has an Earnings ESP of +2.67% and a Zacks Rank #3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Will Chicken Segment Drive Tyson Foods' (TSN) Q3 Earnings?
Tyson Foods, Inc. (TSN - Free Report) is scheduled to release third-quarter fiscal 2019 results on Aug 5. This renowned meat products company’s earnings have outpaced the Zacks Consensus Estimate, with average of 10.2% in the trailing four quarters.
Let’s see what’s in store for the company this time around.
McCormick & Company, Incorporated Price and EPS Surprise
McCormick & Company, Incorporated price-eps-surprise | McCormick & Company, Incorporated Quote
What to Expect?
The Zacks Consensus Estimate for earnings in the third quarter has remained unchanged in the past 30 days at $1.47, indicating a decline from $1.50 reported in the year-ago quarter. The consensus mark for revenues is $11,108 million, implying an increase of 10.5% from the year-ago quarter’s reported figure.
Factors Likely to Drive Tyson Foods
Tyson Foods is likely to gain from its Chicken and Beef segments, given the rising demand for protein. Notably, the company boasts a rich portfolio of protein-packed brands, the demand for which is growing rapidly across the globe. To this end, the company has also been undertaking acquisitions alongside offloading certain non-protein businesses. In particular, acquisitions are aiding growth in the Chicken segment and are likely to be a key driver in the quarter to be reported. Notably, the company acquired the Keystone Foods business in November 2018, which is expected to keep bolstering its Chicken and Other segments' performance.
Other notable acquisitions of Tyson Foods in the past include AdvancePierre and Original Philly Holdings. Also, the company has acquired poultry rendering and blending assets of AMPRO Products, Inc. and American Proteins, Inc. This has enabled Tyson Foods to bolster animal products recycling capabilities, which will aid in expanding the animal feed business. Apart from this, the company is likely to benefit from its focus on alternative sources for meat and protein products, evident from its investments in Beyond Meat and Memphis Meats.
Hurdles in the Path
Lower sales in the Pork and Prepared Foods categories have been weighing on the company’s top-line performance. While Pork segment sales were hurt by lower average sale price, the performance of the Prepared Foods category has been bearing the brunt of business divestitures. Also, input costs in the Prepared Foods category are expected to rise during the third and fourth quarters of fiscal 2019, owing to higher price of beef and pork stemming from the concerns regarding the outbreak of African swine fever in China. This poses a threat to the bottom line.
What the Zacks Model Unveils
Our proven model doesn’t conclusively predict a beat for Tyson Foods this earnings season. For this to happen, a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Though Tyson Foods carries a Zacks Rank #3, it has an Earnings ESP of 0.00%, which makes surprise prediction difficult.
Stocks Poised to Beat Earnings Estimates
Estee Lauder (EL - Free Report) currently has an Earnings ESP of +2.46% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
General Mills (GIS - Free Report) presently has an Earnings ESP of +0.97% and a Zacks Rank #2.
Kraft Heinz (KHC - Free Report) currently has an Earnings ESP of +2.67% and a Zacks Rank #3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>